G
Glenn Dranoff
Researcher at Novartis
Publications - 201
Citations - 26166
Glenn Dranoff is an academic researcher from Novartis. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 74, co-authored 190 publications receiving 22205 citations. Previous affiliations of Glenn Dranoff include Johns Hopkins University School of Medicine & Harvard University.
Papers
More filters
Journal ArticleDOI
Combining immunotherapy and targeted therapies in cancer treatment
TL;DR: Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clinical outcomes.
Journal ArticleDOI
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama,Esra A. Akbay,Yvonne Y. Li,Grit S. Herter-Sprie,Kevin A. Buczkowski,William G. Richards,Leena Gandhi,Amanda J. Redig,Scott J. Rodig,Hajime Asahina,Robert E. Jones,Meghana M. Kulkarni,Mari Kuraguchi,Sangeetha Palakurthi,Peter E. Fecci,Bruce E. Johnson,Pasi A. Jänne,Jeffrey A. Engelman,Sidharta P. Gangadharan,Daniel B. Costa,Gordon J. Freeman,Raphael Bueno,F. Stephen Hodi,Glenn Dranoff,Kwok-Kin Wong,Peter S. Hammerman,Peter S. Hammerman +26 more
TL;DR: Analysis of the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma suggests that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.
Journal ArticleDOI
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
Esra A. Akbay,Esra A. Akbay,Shohei Koyama,Julian Carretero,Abigail Altabef,Abigail Altabef,Jeremy H. Tchaicha,Jeremy H. Tchaicha,Camilla L. Christensen,Camilla L. Christensen,Oliver Mikse,Oliver Mikse,Andrew D. Cherniack,Ellen M. Beauchamp,Trevor J. Pugh,Matthew D. Wilkerson,Peter E. Fecci,Mohit Butaney,Jacob B. Reibel,Jacob B. Reibel,Margaret Soucheray,Travis J. Cohoon,Travis J. Cohoon,Pasi A. Jänne,Matthew Meyerson,Matthew Meyerson,D. Neil Hayes,Geoffrey I. Shapiro,Takeshi Shimamura,Lynette M. Sholl,Scott J. Rodig,Gordon J. Freeman,Peter S. Hammerman,Glenn Dranoff,Kwok-Kin Wong +34 more
TL;DR: It is shown that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines.
Journal ArticleDOI
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas,Alissa C. Baker,Ralph M. Debiasi,Ralph M. Debiasi,Wendy Winckler,Wendy Winckler,Thomas LaFramboise,Thomas LaFramboise,William M. Lin,William M. Lin,Meng Wang,Meng Wang,Whei Feng,Whei Feng,Thomas Zander,Laura E. MacConnaill,Laura E. MacConnaill,Jeffrey C. Lee,Jeffrey C. Lee,Rick Nicoletti,Rick Nicoletti,Charlie Hatton,Charlie Hatton,Mary Goyette,Luc Girard,Kuntal Majmudar,Liuda Ziaugra,Kwok-Kin Wong,Stacey Gabriel,Rameen Beroukhim,Rameen Beroukhim,Michael Peyton,Jordi Barretina,Jordi Barretina,Amit Dutt,Amit Dutt,Caroline Emery,Heidi Greulich,Heidi Greulich,Kinjal Shah,Kinjal Shah,Hidefumi Sasaki,Adi F. Gazdar,John D. Minna,Scott A. Armstrong,Ingo K. Mellinghoff,F. Stephen Hodi,Glenn Dranoff,Paul S. Mischel,Timothy F. Cloughesy,Stan F. Nelson,Linda M. Liau,Kirsten D. Mertz,Kirsten D. Mertz,Mark A. Rubin,Holger Moch,Massimo Loda,William J. Catalona,Jonathan A. Fletcher,Sabina Signoretti,Frederic J. Kaye,Kenneth C. Anderson,George D. Demetri,Reinhard Dummer,Stephan N. Wagner,Meenhard Herlyn,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Levi A. Garraway,Levi A. Garraway +71 more
TL;DR: High-throughput genotyping is adapted to query 238 known oncogene mutations across 1,000 human tumor samples and established robust mutation distributions spanning 17 cancer types, offering a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time'.
Journal ArticleDOI
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. Stephen Hodi,Martin C. Mihm,Robert J. Soiffer,Frank G. Haluska,Marcus O. Butler,Michael V. Seiden,Thomas A. Davis,Rochele Henry-Spires,Suzanne MacRae,Ann Willman,Robert F. Padera,Michael T. Jaklitsch,Sridhar Shankar,Teresa C. Chen,Alan J. Korman,James P. Allison,Glenn Dranoff +16 more
TL;DR: Findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients.